MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Endocrinology & Metabolic Diseases
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)*
Organization & Developments: NewAmsterdam Pharma
Parents
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)*
Children
* Developing safe, convenient, oral medications for metabolic diseases to help transform the treatment paradigm for these patients.
*Providing therapies for patients suffering from an array of conditions where aberrant cholesterol metabolism underlies significant morbidity and mortality despite treatment with existing standards of care.
2024: NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
2024: NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts_ seekingalpha.com
2024: Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies_seekingalpha.com
2025: NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
2025: NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution
2025: NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
2025: NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials
Jumps
Finance & Acquisition: NewAmsterdam Pharma
Key People: NewAmsterdam Pharma